





CHARITÉ/BIH-PARTNER WANTED!

Short profile

Name: Acumen Diagnostics

Medical field	Infectious diseases
Product type	Medical devices, diagnostics and therapeutics
Growth stage	Development
Team	30 people

Description of product:

Unyvero A30 SHR (Sepsis Host Response) is a blood-based, host response gene expression test, used to diagnose sepsis. A30 SHR can help doctors to quickly and accurately assess whether or not an infection condition in a patient has a risk of complication and developing into sepsis. Early and accurate diagnosis result of A30 SHR can also help doctors to determine the appropriate next steps for patient management.

Desired project goal: Please also elaborate on the primary outcome

The company would like to test-bed their new Unyvero A30 SHR test that will develop AcuSept (sepsis host-response PCR test function) into Unyvero A30 cartridge and instrument platform. To do so, the company is intending to conduct a (i) pre-clinical trial including feasibility studies, design and development and bench testing; as well as (ii) clinical trial with around 200 patients to be recruited in Germany. The company would like to collaborate with Charité to define study protocol and regulatory compliance regulations.

Desired project type: Please also elaborate on the following points, if applicable: population, intervention, study design etc.

Test bedding and validation.



+65 9028 5892

 \mathbb{M}

www.acumen-diagnostics.com

ong@acumen-diagnostics.com

